Chest, Vol 86, 723-728, Copyright © 1984 by American College of Chest Physicians

ARTICLES

Severe bleomycin-induced pneumonitis. Clinical features and response to corticosteroids

DA White and DE Stover

Ten (3 percent) of 287 patients receiving combination chemotherapy developed severe bleomycin-induced pneumonitis. The course and the response to therapy in these patients are summarized in this report. The dose of bleomycin received varied from 136 to 588 units, with toxic effects occurring in six patients who had received less than 200 units. Dyspnea and dry cough were the presenting symptoms in nine patients; one was asymptomatic. Roentgenograms were abnormal in nine cases, with five showing bilateral infiltrates. Four patients had asymmetric abnormalities, with radiographic involvement of only a single lung in two of these. Pulmonary function tests were abnormal, with a decreased diffusing capacity. Seven patients were treated with corticosteroid therapy, and significant clinical and radiographic improvement was noted; however, pulmonary function tests remained abnormal and could not be used to monitor the response. Prolonged therapy with corticosteroids was required over many months to maintain improvement. Tapering of the steroid dosage led to recurrence of clinical symptoms and radiographic infiltrates in five patients. Mortality was 60 percent, with three early deaths in untreated patients and three late deaths which occurred 12 to 15 months after diagnosis. In this study, patients with severe bleomycin-induced pneumonitis had symptomatic improvement and roentgenographic clearing following corticosteroid therapy.

This article has been cited by other articles:

				M. C. B. Godoy, D. Nonaka, B. G. Raphael, and I. Vlahos Diffuse Ground-Glass Opacities in a Patient With Hodgkin Lymphoma and Progressive Respiratory Failure Chest, July 1, 2008; 134(1): 207 - 212. [Full Text] [PDF]

				S J Bourke Interstitial lung disease: progress and problems. Postgrad. Med. J., August 1, 2006; 82(970): 494 - 499. [Abstract] [Full Text] [PDF]

				S. Sleijfer Bleomycin-Induced Pneumonitis Chest, August 1, 2001; 120(2): 617 - 624. [Abstract] [Full Text] [PDF]

				J. Goffin, H. Kreisman, and V. Sandor Bleomycin-Induced Lung Toxicity and Pentoxifylline J. Clin. Oncol., January 15, 2001; 19(2): 597 - 598. [Full Text] [PDF]

				M. A. JANTZ and S. A. SAHN Corticosteroids in Acute Respiratory Failure Am. J. Respir. Crit. Care Med., October 1, 1999; 160(4): 1079 - 1100. [Full Text]

				D. M Mitchell and A. Woodcock Introduction Thorax, August 1, 1999; 54(90002): S1 - 1. [PDF]

				E. Sato, S. Koyama, T. Masubuchi, A. Takamizawa, K. Kubo, S. Nagai, and T. Izumi Bleomycin stimulates lung epithelial cells to release neutrophil and monocyte chemotactic activities Am J Physiol Lung Cell Mol Physiol, June 1, 1999; 276(6): L941 - L950. [Abstract] [Full Text] [PDF]

				A. Takamizawa, S. Koyama, E. Sato, T. Masubuchi, K. Kubo, M. Sekiguchi, S. Nagai, and T. Izumi Bleomycin Stimulates Lung Fibroblasts to Release Neutrophil and Monocyte Chemotactic Activity J. Immunol., May 15, 1999; 162(10): 6200 - 6208. [Abstract] [Full Text] [PDF]

				B. T. SOCIETY and S. O. C. COMMITTEE The Diagnosis, Assessment and Treatment of Diffuse Parenchymal Lung Disease in Adults---British Thoracic Society recommendations Thorax, April 1, 1990; 54(90001): 1S - 28. [Full Text]